Roche's move for the asset comes shortly after Zealand started the phase 2b ZUPREME-1 trial of petrelintide in people overweight or obese, and ahead of the ZUPREME-2 study in overweight or obese ...

Zealand Pharma has been collaborating with Roche to advance the development and commercialization of petrelintide as part of its strategy to strengthen its position in the treatment of metabolic ...

The firm’s current valuation of approximately DKK 790 for Zealand Pharma represents their confidence in the company’s growth prospects, particularly with the inclusion of the Roche deal for ...